Navigation Links
US FDA Admits Risks of Mercury Dental Fillings, Settles Lawsuit
Date:6/5/2008

Statement of Michael Bender, Plaintiff

WASHINGTON, June 5 /PRNewswire-USNewswire/ -- "After 32 years of delay, the Food and Drug Administration has finally agreed to comply with the law and set a date to classify mercury amalgam as a substance that poses a health risk to pregnant women and unborn babies, and children. This about-face resulted from settling, earlier this week, our lawsuit, Moms Against Mercury et al. v. Von Eschenbach, Commissioner, et al. The FDA must now finish classification within one year of the close of the public comment period on its amalgam policy, that is, by July 28, 2009. The FDA also agreed to and, with uncharacteristic speed, has already changed its website on mercury amalgam -- dramatically.

Gone are all of FDA's claims that no science exists that amalgam is unsafe, or that other countries have acted for environmental reasons only, or that the 2006 FDA advisory panel affirmed amalgam's safety, all of which are untrue. Instead, the FDA has moved to a more neutral course, while still recognizing the serious health risks posed by amalgam in particular for children and unborn children, for pregnant women, and for those with mercury immuno-sensitivity.

The Updated June 3, 2008 FDA website (see: http://www.fda.gov/cdrh/consumer/amalgams.html) now states, for example:

"Dental amalgams contain mercury, which may have neurotoxic effects on the nervous systems of developing children and fetus."

"Pregnant women and persons who may have a health condition that makes them more sensitive to mercury exposure, including individuals with existing high levels of mercury bioburden, should not avoid seeking dental care, but should discuss options with their health practitioner."

In September 2006, an advisory panel to the FDA reviewed FDA's research and heard presentations from the public about the benefits and risks of mercury and amalgam. The joint committee concluded with personal recommendations by the members. These include that FDA should:

Consider informed consent for patients receiving amalgam

Consider labeling changes restricting its use in pregnant woman and children

Consider the relevancy of the "precautionary principle"

You can read the summary of the FDA advisory panel meeting at: http://www.fda.gov/cdrh/meetings/090606-summary.html

The FDA website now also states that "Some other countries follow a 'precautionary principle' and avoid the use of dental amalgam in pregnant women. The FDA provides links to advice about dental amalgams from regulatory agencies in other countries:

Canada: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/1996/1996_63_e.html

France: http://afssaps.sante.fr/ang/pdf/amalgam.pdf

Sweden: http://www.kemi.se/templates/Page.aspx?id=5233 "

The plaintiffs included a team of four nonprofit groups, two public officials, three dental professionals, and two consumer victims: Moms Against Mercury (Amy Carson and Angela Medlin), Connecticut Coalition for Environmental Justice (Dr. Mark Mitchell), Oregonians for Life (Mary Starrett), mercury expert Michael Bender (as a of the Vermont Advisory Committee on Mercury Pollution), Arizona Senator Karen Johnson, Dr. Andy Landerman, Dr. Corrie Crowe, dental assistant Karen Palmer, consumer advocates Linda Brocato and Anita Vazquez Tibau, and Consumers for Dental Choice.

For More Information: http://www.mercurypolicy.org


'/>"/>
SOURCE Mercury Policy Project
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sutter Admits: Closing St. Lukes Likely to Reduce Charity Care
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Informational handout key to giving parents a better understanding of CT radiation risks
4. Stanford study highlights cost-effective method of lowering heart disease risks
5. Hispanic Teens Take More Skin Cancer Risks
6. Smoking increases risks for head and neck cancers for men and women
7. Case Management Cost-Effective Way to Cut Heart Risks
8. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
9. Diabetes Drug Avandia Boosts Heart Risks: Study
10. Federal research plan to determine nanotech risks fails to deliver
11. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/23/2017)... ... 2017 , ... In 2016 the World Health Organization declared the Zika virus ... Zika-related cases in the Americas within the next year. Lyme disease is one of ... skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses are ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating ... communities, 16 more public health departments have been awarded national accreditation through the ... million people into the expanding network of communities across the nation whose health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is ... making a huge impact on businesses and individual consumers alike. Laboratories can maximize ... have a value anywhere from $4 trillion to $11 trillion dollars by the year ...
(Date:3/23/2017)... , ... March 23, 2017 ... ... financial services firm serving the families and businesses of the Norwalk and ... program. Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... India , March 24, 2017 A ... market has been growing rapidly as the global sales of Adcetris ... the growth in the antibody drug conjugates market is driven by ... of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology: